New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
Hugh Bettesworth, CEO, Mirada Medical, explores how AI autocontouring technology can help tackle the cancer care backlog as a result of the COVID-19 pandemic.
New data from the REACT study finds that the rising infection rate has steadied a little, but there is no "sharp drop in infections" as in the first wave and the R is still high.
The company announced that their current vaccine can handle the South African COVID mutation - with plans to create an "additional booster dose" to see if they can create specific protections against emerging variants.
Professor Herb Sewell, expert in immunology, wrote that the UK Government should not rely on one dose of the vaccine - suggesting that the diluted vaccine could encourage mutations to evolve.
New data from the REACT study says that there have been more than 20 hospitals' worth of new patients since Christmas Eve, putting "extreme pressure" on the NHS.
Unidos En Salud organisers have now provided COVID-19 testing to 14,000 people, targeting Latinx workers - one of the most hard-hit communities in San Francisco.